Humalog Mix 25 - instructions for use, dose, side effects, contraindications

Active substanceInsulin lyspro two-phaseInsulin lyspro two-phase

Similar drugsTo uncover

Humalog® Mix 25

suspension PC

Eli Lilly East SA Switzerland

Humalog® Mix 50

suspension PC

Eli Lilly East SA Switzerland

Dosage form: & nbspsubcutaneous suspension

Composition:

In 1 ml contains:

active substance: insulin lyspro 100 ME;

Excipients: metacresol 1,76 mg, phenol liquid 0.80 mg, in terms of 89% phenol 0.715 mg, glycerol (glycerin) 16 mg, protamine sulfate 0.28 mg, sodium hydrogen phosphate 3.78 mg, zinc oxide qs to obtain zinc ions not more than 25 μg, hydrochloric acid solution of 10% and / or sodium hydroxide solution of 10% qs to establish a pH of 7.0-7.8, water for injection up to 1 ml.

Description:

A white suspension that exfoliates to form a white precipitate and a clear, colorless or almost colorless supernatant. The precipitate is easily resuspended by gentle shaking.

Pharmacotherapeutic group:Hypoglycemic agent is a combination of insulin analogues of short and medium duration of action

ATX: & nbsp

A.10.A.B.04 Insulin LizPro

Pharmacodynamics:

Humalog® Mix 25 is a ready-made mixture consisting of a 25% insulin solution of lyspro (high-speed analog of human insulin) and a protamine suspension of insulin lyspro 75% (analog of human insulin of average duration of action).

The main effect of insulin lispro is the regulation of glucose metabolism.

In addition, it has an anabolic and anti-catabolic effect on various tissues of the body. In muscle tissue there is an increase in the content glycogen, fatty acids, glycerol, increased protein synthesis and increased consumption of amino acids, but there is a decrease in glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and release of amino acids.

Shown, that insulin lyspro is equimolar to human insulin, but its effect comes faster and lasts less. The beginning of the drug - about 15 minutes, which allows you to enter the drug immediately before meals (0-15 minutes before meals), compared with the usual human insulin. Completeness of absorption and the beginning of the effect of insulin depends on the place of administration (abdomen, thigh, buttocks), dose (volume of insulin administered), blood supply, body temperature and physical activity.

After a subcutaneous injection of Humalog® Miks 25, a rapid onset of action and an early onset of the peak in insulin activity of lyspro is observed. The profile of the action of insulin lispro protamine is similar to that of normal insulin-isophane with a duration of about 15 hours.

Pharmacokinetics:

The pharmacokinetics of insulin lispro is characterized by rapid absorption and reaching a maximum concentration in the blood 30-70 minutes after subcutaneous injection.

The pharmacokinetics of the insulin suspension of lyspro protamine is similar to that of insulin of average duration of action (NPH). The pharmacokinetics of the preparation Humalog® Mix 25 is determined by the individual pharmacokinetic properties of the two components of the preparation.

With the introduction of insulin lizpro, faster absorption is observed compared to soluble human insulin in patients with renal insufficiency. In patients with type 2 diabetes mellitus, the pharmacokinetic differences between insulin lispro and soluble human insulin are observed in a wide range of kidney function regardless of renal function. With the introduction of insulin lispro, faster absorption and faster elimination than soluble human insulin in patients with hepatic insufficiency is noted.

Indications:

Diabetes mellitus, requiring insulin therapy.

Contraindications:

Hypersensitivity to insulin or to one of the components of the drug.

Hypoglycemia.

Pregnancy and lactation:

Numerous data on the use of insulin lizpro in pregnancy indicate the absence of an undesirable effect of the drug on pregnancy or the condition of the fetus and newborn.

During pregnancy it is especially important to maintain good control in patients receiving insulin therapy. The need for insulin usually decreases during the first trimester and increases during the II and III trimesters. During and immediately after delivery, the need for insulin can dramatically decrease. Patients with diabetes are advised to inform the doctor about pregnancy or about pregnancy planning.

Patients with diabetes during the period of breastfeeding may require a correction of the dose of insulin, diet, or both.

Dosing and Administration:

The preparation Humalog® Mix 25 is administered subcutaneously.

The dose of Humalog® Mix 25 is determined by the doctor individually depending on the concentration of blood glucose.

Mode of insulin administration is individual.

Intravenous administration of the preparation Humalog® Mix 25 is unacceptable.

The temperature of the drug should be at room temperature.

Subcutaneous injections should be done in the area of the shoulder, hips, buttocks or abdomen. The injection sites need to be alternated so that the same place is used no more often than once a month. With subcutaneous administration of insulin, care should be taken to avoid getting the drug into the lumen of blood vessels. After injection, do not massage the injection site.

Read the recommendations for installing the cartridge into the insulin delivery device and attaching a needle to the insulin before inserting insulin contained in the manufacturer's instructions for the insulin delivery device. It is necessary to strictly follow this instruction.

Preparation for introduction

For the preparation Humalog® Mix 25 in cartridges

Immediately before use, the Humalog® Mix 25 cartridge should be rolled between the palms ten times and shaken 180 degrees also ten times to resuspend insulin until it becomes a homogeneous cloudy liquid or milk. Do not shake vigorously, as this can lead to the appearance of foam, which may interfere with the correct dose set.To facilitate mixing, the cartridge contains a small glass bead.

Do not use insulin if there are flakes after mixing.

For the preparation Humalog® Mix 25 in the QuickK pen

Before the injection, it is necessary to read the using the QuickKenny ™ syringe pen.

Dosing Introduction

1. Wash your hands.

2. Choose a place for injection.

3. Prepare the skin at the injection site in accordance with the doctor's recommendations.

4. Remove the outer protective cap from the needle.

5. Fix the skin, collecting it in a large crease.

6. Insert the needle subcutaneously into the collected fold and perform the injection according to the instructions for using the syringe pen.

7. Remove the needle and gently squeeze the injection site with a cotton swab for a few seconds. Do not rub the injection site.

8. Using the outer protective cap of the needle, unscrew the needle and dispose of it.

9. Put the cap on the syringe pen.

For the preparation Humalog® Mix 25 with the KvikPen syringe pen™

Before administering the injection, it is necessary to read the manual for the use of the QUIKPEN pen syringe.

Side effects:

Hypoglycaemia is the most common side effect that occurs with the administration of insulin preparations, including Humalog® Mix 25. Severe hypoglycemia can lead to loss of consciousness and, in exceptional cases, death.

Allergic reactions: patients may experience local allergic reactions in the form of redness, swelling, or itching at the injection site. These reactions usually stop for a period of several days to several weeks. In a number of cases, these reactions can be caused by causes not associated with insulin, for example, skin irritation with a cleansing agent or with improper injection.

Systemic allergic reactions, caused by insulin, appear less often, but are more serious. They can manifest generalized itching, difficulty breathing, shortness of breath, lower blood pressure, increased heart rate, increased sweating. Severe cases of systemic allergic reactions can be life threatening. In rare cases of severe allergy to Humalogo® Mix 25, immediate treatment is required. It may be necessary to change insulin, or conduct desensitization.

With prolonged use, it is possible to develop lipodystrophy at the injection site.

Spontaneous messages

There were revealed cases of edema development, mainly with fast normalization of blood glucose concentration against intensive insulin therapy at baseline unsatisfactory glycemic control (see section "Special instructions").

Overdose:

An overdose of insulin causes hypoglycemia, accompanied by the following symptoms: lethargy, increased sweating, tachycardia, pallor of the skin, headache, trembling, vomiting, confusion. Under certain conditions, for example, with a long duration of the disease or with intensive control of diabetes mellitus, the symptoms-precursors of hypoglycemia may change.

Light states of hypoglycemia can usually be suppressed by ingesting glucose or sugar. You may need to adjust the dose of insulin, diet or physical activity.

Correction of moderate hypoglycemia can be carried out by intramuscular or subcutaneous administration of glucagon, followed by ingestion of carbohydrates.

Severe hypoglycemia, accompanied by coma, convulsions or neurological disorders, is stopped by intramuscular / subcutaneous administration of glucagon or by intravenous administration of a concentrated solution of glucose. After the restoration of consciousness, the patient needs to give food rich in carbohydrates, in order to avoid the re-development of hypoglycemia.

It may be necessary to continue taking carbohydrates and monitoring the patient, since there may be a relapse of hypoglycemia.

Interaction:

The hypoglycemic effect of Humalog® Mix 25 is reduced when co-administered with the following medicines: oral contraceptives, glucocorticosteroids, iodine-containing thyroid hormones, danazol, beta₂-adrenomimetics (for example, ritodrin, salbutamol, terbutaline), thiazide diuretics, chloroprotoxen, diazoxide, isoniazid, a nicotinic acid, phenothiazine derivatives.

Hypoglycemic effect of the preparation Humalog® Mix 25 enhances: beta-blockers, ethanol and ethanol containing drugs, anabolic steroids, fenfluramine, guanethidine, tetracyclines, oral hypoglycemic drugs, salicylates (for example, acetylsalicylic acid), sulfonamide antibiotics, some antidepressants (monoamine oxidase inhibitors), angiotensin converting enzyme inhibitors (captopril, enalapril), octreotide, lithium preparations, angiotensin II receptor antagonists.

Beta-adrenoblockers, clonidine, reserpine can mask the manifestation of symptoms of hypoglycemia.

The interaction of Humalog® Mix 25 with other insulin preparations has not been studied.

If you need to use other drugs in addition to insulin, you should consult your doctor (see section "Special instructions").

Special instructions:

Transfer of the patient to another type or preparation of insulin with a different trade name should occur under strict medical supervision. Changes in the activity, a brand (manufacturer) Type (Regular, NPH, etc.), specific accessory (animal, human, human insulin analog) and / or the production method (DNA recombinant insulin or animal insulin) can lead to the need for dose adjustment.

For some patients, when switching from animal insulin to human insulin, it may be necessary to adjust the dose.This can happen even with the first injection of a human insulin preparation or gradually for several weeks or months after the transfer.

Unadjusted hypoglycemic or hyperglycemic reactions can cause loss of consciousness, to whom or death. Symptoms-precursors

hypoglycemia may change or be less pronounced with prolonged course of diabetes mellitus, diabetic neuropathy, or treatment with drugs such as beta-adrenoblockers.

The use of inadequate doses or discontinuation of treatment, especially in patients with type 1 diabetes, can lead to hyperglycemia and diabetic ketoacidosis (potentially potentially life-threatening conditions).

The need for insulin may decrease with renal insufficiency, as well as in liver failure due to a decrease in the ability to gluconeogenesis and reduce the metabolism of insulin; However, in patients with chronic hepatic insufficiency, increased insulin resistance may lead to an increase in the need for it.

The need for insulin can increase with certain diseases or emotional overstrain.Correction of the dose of insulin may also be required when patients increase their physical activity or when changing their usual diet. Physical stress can lead to an increased risk of developing

hypoglycemia.

When using insulin preparations in combination with drugs of the thiazolidinedione group, the risk of edema and chronic heart failure increases, especially in patients with cardiovascular disease and the presence of risk factors for chronic heart failure.

To avoid possible transmission of an infectious disease, each cartridge / syringe pen should be used by only one patient, even if the needle is replaced. Cartridges with the preparation Humalog® Mix 25 should be used with CE-marked syringes, in accordance with the instructions of the device manufacturer.

GUIDE FOR USING THE SYRINGE-HANDLE QuickKenny ™

Humalog® QuickPan ™, Humalog® Mix 25 QuickPan ™, Humalog® Mix 50 QuickPan ™

100 IU / ml, 3 ml

SPRIC-HANDLE FOR INSULIN INTRODUCTION

See Fig. 1

PLEASE READ THESE INSTRUCTIONS BEFORE APPLICATION

Introduction

The QuickK pen is easy to use.It is a device for the introduction of insulin (an "insulin syringe pen") containing 3 ml (300 units) of an insulin preparation with an activity of 100 IU / ml. You can administer 1 to 60 units of insulin per injection. You can set the dose to within one unit. If you have set too many units. You can correct the dose without losing insulin.

Before using the QuickKP pen, read this manual completely and follow its instructions carefully. If you do not fully comply with these instructions, then you can get either too low or too high a dose of insulin.

Your syringe Penkin Pen for insulin administration should only be used for your injections. Do not pass the syringe pen or needle to others, as this can lead to transmission of the infection. For each injection, use a new needle.

DO NOT USE a syringe pen if any of its parts is damaged or broken. Always have a spare syringe-pen in case you lose a syringe pen or it will be damaged.

It is not recommended to use a syringe pen for patients with complete loss of sight or with impaired vision without the help of well-seeing people trained in the use of a syringe pen.

Preparing the QuickK pen

Important notes:

- Read and follow the instructions for use described in the Instruction for Use.

- Check the label on the syringe pen before each injection to make sure the drug has not expired and you are using the right type of insulin; Do not remove the label from the syringe pen.

Note: The color of the dose button of the QUIKPEN pen syringe corresponds to the color of the strip on the label of the pen syringe and depends on the type of insulin. In this manual, the dose button is grayed out. The blue color of the body of the QuickK pen syringe indicates that it is intended for use with the products of the Humalog line.

Color marking of the dose introduction button - see Fig. 2.

- Your doctor wrote you the most suitable type of insulin. Any changes in insulin therapy should be performed only under the supervision of the attending physician.

- It is recommended to use the KvikPen syringe pen with needles from Becton, Dickinson and Company (BD) for pen syringes.

- Before using the syringe pen, make sure that the needle is fully attached to the syringe handle.

- Follow the instructions given below.

Frequently Asked Questions about preparing a QUIKPEN pen syringe for use

- What should my insulin look like? Some insulin preparations are cloudy suspensions, while others are clear solutions; be sure to read the description of insulin in the enclosed Instruction for Use.

- What should I do if the dose prescribed to me is more than 60 units? If your dose is more than 60 units, you will need a second injection, or you can contact the doctor in charge.

- Why should I use a new needle for each injection? If the needles are reused, you may receive an incorrect dose of insulin, the needle may become clogged, or the syringe pen will start to seize, or you may infect the infection due to a sterility violation.

- What should I do if I'm not sure how much insulin is left in my cartridge? Take the handle so that the tip of the needle is pointing down. The scale on the transparent cartridge holder shows the approximate number of remaining insulin units. These numbers MUST NOT be used to set the dose.

- What should I do if I can not remove the cap from the syringe pen? In order to remove the cap, pull it.If you are having difficulty removing the cap, gently turn the cap clockwise and counterclockwise to release it, then pull it off, remove the cap.

Checking the QUIKPEN syringe pen for insulin delivery

Important notes:

- Check insulin intake every time. Checking the intake of insulin from the syringe-pen should be performed before each injection before the emergence of a trickle of insulin to make sure that the syringe pen is ready for the dose.

- If you do not check the insulin intake before the trickle, you can get too little or too much insulin.

Frequently asked questions about insulin intake check

- Why should I check the insulin intake before each injection?

1. This ensures that the syringe pen is ready for the dose.

2. This confirms that the trickle of insulin exits the needle when you press the dose button.

3. This removes air that can collect in the needle or in the cartridge with insulin during normal use.

- What should I do if I can not fully press the dose button during the QuickKen check onintake of insulin?

1. Attach a new needle.

2. Inspect the insulin intake from the syringe pen.

- What should I do if I see air bubbles in the cartridge?

You must check the insulin intake from the syringe pen. Remember that you can not store a syringe pen with a needle attached to it, as this can lead to the formation of air bubbles in the cartridge with insulin. A small air bubble does not affect the dose, and you can enter your dose as usual.

Administration of the required dose

Important notes:

- Observe the rules of asepsis and antiseptics, recommended by the attending physician.

- Make sure that you have entered the desired dose by pressing and holding the dose button, and slowly count to 5 before removing the needle. If the insulin drips from the needle, most likely, you did not hold the needle under the skin long enough.

- The presence of a drop of insulin at the tip of the needle - this is normal. This will not affect your dose.

- The syringe pen will not allow you to dial a dose exceeding the number of units of insulin left in the cartridge.

- If you doubt that you have taken the full dose, do not administer another dose.Call the Lilly office or ask your doctor for help.

- If your dose exceeds the number of units left in the cartridge, you can enter the remaining amount of insulin in this syringe pen and then use a new pen to complete the required dose, OR EVERYTHING the necessary dose using a new syringe pen.

- Do not attempt to inject insulin by turning the dose button. You will NOT get insulin if you turn the dose button. You must PUT on the dose button on a straight axis in order to get a dose of insulin.

- Do not try to change the dose of insulin during the injection.

- The used needle should be disposed of in accordance with local medical waste disposal requirements.

- Remove the needle after each injection.

Frequently Asked Questions for Dose Administration

- Why is it difficult to press the dose button, the cord I try to inject?

1. Your needle may be clogged. Attempt to attach a new needle. Once you do this, you can see how the insulin exits the needle. Then, check the syringe pen for insulin.

2.A quick push of a dose button may make pressing a button hard. A slower depression of the dose button may make pressing easier.

3. Using a larger diameter needle will make it easier to press the dose button during the injection.

Consult your doctor to determine the size of the needle you are most likely to use.

4. If pressing the button when the dose is administered remains tight after all the above items have been completed, the syringe pen must be replaced.

- What should I do if the Quickkien pen gets stuck when used?

Your syringe stickles up if it is difficult to inject or set a dose. In order for the syringe pen to not seize:

1. Attach a new needle. Once you do this, you can see how the insulin exits the needle.

2. Inspect the insulin intake.

3. Set the desired dose and perform the injection.

Do not attempt to lubricate the syringe handle, as this may damage the mechanism of the syringe handle.

Pressing the button to enter the dose can become taut if foreign impurities (dirt, dust, food, insulin or any liquids) get inside the syringe pen.Do not allow foreign matter to enter the syringe handle.

- Why does insulin leak out of the needle after I have finished administering my dose?

You probably took the needle out of the skin too quickly.

1. Make sure that you see the number "0" in the dose indicator window.

2. For the next dose, press and hold the dose button and slowly count to 5 before removing the needle.

- What should I do if my dose is set, and the dose button accidentally found to be drowned in without a needle attached to the syringe pen?

1. Turn the dose button back to zero.

2. Attach a new needle.

3. Inspect your insulin intake.

4. Set the dose and perform the injection.

- What should I do if I have set the wrong dose (too low or too high)? Turn the dose button back or forward to correct the dose.

- What should I do if I see that the insulin is flowing out of the needle of the syringe pen during the selection or correction of the dose? Do not administer a dose, as you may not receive your full dose. Set the syringe pen to the number zero and again check the insulin intake from the syringe pen (see "Checking the QUIKPEN syringe pen for insulin delivery"). Set the dose and inject.

- What should I do if my full dose can not be established? The syringe pen will not allow you to set a dose that exceeds the number of units of insulin left in the cartridge. For example, if you need 31 units, and only 25 units remain in the cartridge, you can not go through the figure at the time of installation. Do not try to set the dose by going through this figure. If the partial dose is left in the syringe pen, then you can either:

1. Enter this partial dose, and then enter the remaining dose using a new syringe pen, or

2. Enter the full dose from the new pen-syringe.

- Why can not I set a dose to use the small amount of insulin that is left in my cartridge? The syringe pen is designed to provide at least 300 insulin units. The device of the syringe-pen protects the cartridge from complete emptying, since the small amount of insulin that remains in the cartridge can not be entered with the necessary accuracy.

Storage and disposal

Important notes:

- The syringe pen can not be used if it is outside the refrigerator for more than the time specified in the Instruction for Use.

- Do not store the syringe pen with the needle attached to it. If the needle is left attached, insulin can leak out of the pen syringe, or insulin may dry up inside the needle, causing clogging of the needle, or air bubbles may form inside the cartridge.

- Syringe pens that are not in use should be stored in the refrigerator at a temperature of 2 ° C to 8 ° C. Do not use a syringe pen if it has been frozen.

- The syringe pen you are currently using should be stored at a temperature not exceeding 30 ° C and in a place protected from heat and light.

- Refer to the instructions for use to fully understand the storage conditions of the syringe pen.

- Keep the syringe pen out of the reach of children.

- Dispose of used needles in puncture-resistant, closed containers (for example, in biohazard containers or waste containers), or as recommended by your doctor.

- Dispose used disposable syringes without needles attached to them and in accordance with the recommendations of your doctor.

- Do not re-use the filled container for sharp objects.

- Ask your doctor about possible ways to dispose of filled sharps containers that are available in your area.

- Recommendations for handling needles do not replace local rules for disposal, rules recommended by the doctor in charge or departmental requirements.

Humalog®, Humalog® in the KvikPen ™ syringe handle, Humalog® Mix 50 in the KvikPen ™ syringe handle, Humalog® Mix 25 in the KvikPen ™ pen syringe are trademarks of Eli Lilly and Company.

Date of approval:

The QUIKPEN ™ syringe pen meets the requirements of precise dosing and the functional requirements of ISO 11608 1: 2000

Preparation

Make sure you have the following components:

□ Syringe handle

□ New needle for syringe pen

□ A swab moistened with alcohol

Components of the pen-handle QUIKPEN and needles * (* sold separately); parts of the syringe-pen - see Fig. 3.

Color marking of the dose introduction button - see Fig. 2.

Common use of the syringe pen

Follow these instructions to complete each injection.

1.Preparation of pen syringes

Pull the cap of the syringe pen to remove it. Do not rotate the cap.Do not remove the label from the syringe pen.

Be sure that you have checked your insulin on:

- Type of insulin

- Expiration date

- Appearance

Attention: Always read the text on the label of the syringe pen to make sure that you are using the right type of insulin.

Only for insulin suspensions:

Carefully roll the syringe pen 10 times between the palms and turn the syringe handle 10 times.

Stirring is important in order to be sure of getting the right dose. Insulin should look uniformly mixed.

AT.

Take a new needle.

Remove the paper sticker from the outer needle cap.

Use a tampon moistened with alcohol to wipe the rubber disc on the end of the cartridge holder.

Put the needle in the cap, straight on the axis on the syringe-pen.

Screw the needle until the connection is complete.

2. Checking the QUIKPEN syringe pen for insulin delivery

Caution: If you do not check insulin intake before each injection, you can get either too low or too high a dose of insulin.

Remove the outer needle cap. Do not throw it away.

Remove the inner needle cap and discard it.

Set 2 units by rotating the dose introduction button.

AT.

Point the syringe up.

Tap on the cartridge holder so that the air collects at the top.

- With the needle pointing up, press the dose button until it stops and the number of "0" appears in the dose indicator window.

- Keep the dose button in the recessed position and count slowly until 5.

- Insulin intake check is considered to be performed when an insulin stream appears on the end of the needle.

- If the trickle of insulin does not appear at the end of the needle, then repeat the steps of checking insulin intake four times, starting at point 2B and ending at point 2G.

Note: If you do not see the emergence from the needle of a trickle of insulin, and the dose setting becomes difficult, then replace the needle and repeat the insulin intake from the syringe pen.

3. Dosing Introduction

Turn the dose button until the number of units you need for injection.

If you accidentally set too many units, you can correct the dose by rotating the dose button in the opposite direction.

Insert the needle under the skin using the injection technique recommended by your doctor.

Put your thumb on the dose introduction button and firmly press the dose introduction button until it stops completely.

To enter the full dose, hold the dose button and slowly count to 5.

Remove the needle from under the skin.

Note: Check and make sure that you see the number "0" in the dose indicator window, in order to confirm that you have entered the full dose.

AT.

Carefully place the outer cap on the needle.

Note: Remove the needle after each injection to prevent air bubbles from entering the cartridge.

Do not store a syringe pen with a needle attached to it.

Unscrew the needle with the outer cap on it and dispose of it according to the instructions of the attending physician.

Put the cap on the syringe-pen, combining the cap of the cap with the dose indicator, pushing the cap straight on the axis to the syringe-pen.

Example:

Shows 15 units (see Fig. 4).

Even numbers are printed in the dose indicator window in the form of numbers, odd numbers are printed as straight lines between even numbers.

Note: The syringe pen will not allow you to set the number of units greater than the number of units left in the syringe pen.

If you are not sure that you have entered the full dose, do not enter another dose.

Effect on the ability to drive transp. cf. and fur:

During hypoglycemia, the patient's concentration and speed of psychomotor reactions may decrease. This can be dangerous in situations in which these capabilities are particularly needed (for example, driving vehicles or controlling mechanisms).

It should be recommended that patients take precautions to avoid hypoglycemia while driving vehicles and controlling mechanisms. This is especially important for patients with mild or absent symptoms-precursors of hypoglycemia or with frequent development of hypoglycemia. In such cases, the doctor should assess the appropriateness of driving the patient vehicles and machinery management.

Form release / dosage:

Suspension for subcutaneous administration, 100 IU / ml.

Packaging:

Cartridges:

3 ml per cartridge of neutral glass. Five cartridges are placed in a blister. One blister, together with the instruction for use, is placed in a cardboard pack.

In addition, in the case of packaging of the drug at the Russian company JSC "ORTAT", a control sticker for the first autopsy is applied.

Syringe handle QuickKenny^TM:

Or the cartridge is placed in a penstick-Penkin Pen^tm. Five syringe pens along with the instructions for use and the Manual on the use of the syringe-pen are placed in a pack of cardboard. In addition, in the case of packaging of the drug at the Russian company JSC "ORTAT", a control sticker for the first autopsy is applied.

Storage conditions:

At a temperature of 2-8 ° C. Protect from direct sunlight and heat. Do not freeze.

The drug in use in the cartridge should be stored at a temperature of no higher than 30 ° C for up to 28 days.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date indicated on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N011947 / 01

Date of registration:28.04.2011 / 10.10.2016

Expiration Date:Unlimited

The owner of the registration certificate:Eli Lilly East SAEli Lilly East SA Switzerland